SOL-GEL TECHNOLOGIES LTD (SLGL)

IL0011417206 - Common Stock

0.9798  -0.67 (-40.62%)

After market: 0.8501 -0.13 (-13.24%)

Fundamental Rating

4

Taking everything into account, SLGL scores 4 out of 10 in our fundamental rating. SLGL was compared to 193 industry peers in the Pharmaceuticals industry. SLGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SLGL shows excellent growth, but is valued quite expensive already.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLGL had negative earnings in the past year.
SLGL had a negative operating cash flow in the past year.
In the past 5 years SLGL reported 4 times negative net income.
SLGL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -35.51%, SLGL is in line with its industry, outperforming 48.95% of the companies in the same industry.
The Return On Equity of SLGL (-42.73%) is better than 60.53% of its industry peers.
Industry RankSector Rank
ROA -35.51%
ROE -42.73%
ROIC N/A
ROA(3y)-29.16%
ROA(5y)-35.43%
ROE(3y)-33.35%
ROE(5y)-40.91%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

SLGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SLGL has more shares outstanding
The number of shares outstanding for SLGL has been increased compared to 5 years ago.
SLGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -5.40, we must say that SLGL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.40, SLGL is not doing good in the industry: 65.79% of the companies in the same industry are doing better.
There is no outstanding debt for SLGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.4
ROIC/WACCN/A
WACC9.36%

2.3 Liquidity

SLGL has a Current Ratio of 7.36. This indicates that SLGL is financially healthy and has no problem in meeting its short term obligations.
SLGL's Current ratio of 7.36 is fine compared to the rest of the industry. SLGL outperforms 77.89% of its industry peers.
SLGL has a Quick Ratio of 7.36. This indicates that SLGL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.36, SLGL is in the better half of the industry, outperforming 78.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.36
Quick Ratio 7.36

More info and screens

7

3. Growth

3.1 Past

SLGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.81%, which is quite impressive.
Looking at the last year, SLGL shows a very strong growth in Revenue. The Revenue has grown by 873.15%.
SLGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 64.25% yearly.
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.24%
Revenue 1Y (TTM)873.15%
Revenue growth 3Y-43.83%
Revenue growth 5Y64.25%
Sales Q2Q%2416.9%

3.2 Future

SLGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.10% yearly.
The Revenue is expected to grow by 94.55% on average over the next years. This is a very strong growth
EPS Next Y43.95%
EPS Next 2Y23.3%
EPS Next 3Y19.75%
EPS Next 5Y17.1%
Revenue Next Year567.53%
Revenue Next 2Y147.4%
Revenue Next 3Y94.6%
Revenue Next 5Y94.55%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as SLGL's earnings are expected to grow with 19.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.3%
EPS Next 3Y19.75%

More info and screens

0

5. Dividend

5.1 Amount

SLGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOL-GEL TECHNOLOGIES LTD

NASDAQ:SLGL (12/24/2024, 7:38:04 PM)

After market: 0.8501 -0.13 (-13.24%)

0.9798

-0.67 (-40.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-15 2024-11-15/bmo
Earnings (Next)N/A N/A
Inst Owners26.44%
Inst Owner Change-26.8%
Ins Owners0.31%
Ins Owner ChangeN/A
Market Cap27.30M
Analysts82.5
Price Target5.1 (420.51%)
Short Float %0.52%
Short Ratio0.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)41.99%
Min EPS beat(2)-50.33%
Max EPS beat(2)134.31%
EPS beat(4)3
Avg EPS beat(4)24.81%
Min EPS beat(4)-50.33%
Max EPS beat(4)134.31%
EPS beat(8)4
Avg EPS beat(8)-21.82%
EPS beat(12)8
Avg EPS beat(12)12.21%
EPS beat(16)11
Avg EPS beat(16)12.65%
Revenue beat(2)1
Avg Revenue beat(2)170.27%
Min Revenue beat(2)-64.86%
Max Revenue beat(2)405.4%
Revenue beat(4)2
Avg Revenue beat(4)83.63%
Min Revenue beat(4)-69.84%
Max Revenue beat(4)405.4%
Revenue beat(8)3
Avg Revenue beat(8)17.65%
Revenue beat(12)5
Avg Revenue beat(12)3.79%
Revenue beat(16)7
Avg Revenue beat(16)-2.56%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)2.63%
EPS NY rev (3m)2.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)7.65%
Revenue NY rev (3m)7.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.16
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0.24
BVpS1.25
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.51%
ROE -42.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.16%
ROA(5y)-35.43%
ROE(3y)-33.35%
ROE(5y)-40.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.36
Quick Ratio 7.36
Altman-Z -5.4
F-Score4
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)28.48%
Cap/Depr(5y)40.05%
Cap/Sales(3y)4.48%
Cap/Sales(5y)4.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.24%
EPS Next Y43.95%
EPS Next 2Y23.3%
EPS Next 3Y19.75%
EPS Next 5Y17.1%
Revenue 1Y (TTM)873.15%
Revenue growth 3Y-43.83%
Revenue growth 5Y64.25%
Sales Q2Q%2416.9%
Revenue Next Year567.53%
Revenue Next 2Y147.4%
Revenue Next 3Y94.6%
Revenue Next 5Y94.55%
EBIT growth 1Y38.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-459.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-495%
OCF growth 3YN/A
OCF growth 5YN/A